argenx is expected to report consensus revenue of $1.45 billion and earnings per share of $6.27 for the second quarter of 2026, with the current stock price of $862.93 trading well below the average analyst price target of $1,037.61.
Investors are primarily focused on global Vyvgart net product sales, particularly the commercial scaling of the subcutaneous formulation in chronic inflammatory demyelinating polyneuropathy (CIDP) and generalized myasthenia gravis (gMG).
The company enters this report following a strong first quarter where it beat EPS expectations by over 25%, driven by a 63% year-over-year revenue surge. Markets are also closely monitoring pipeline progress toward "Vision 2030," including upcoming trial readouts for ocular MG and myositis, as argenx transitions into a consistently profitable biotech powerhouse.